Market Movers (8-K)
OID
BioStem Technologies announced a $3 million private placement of common stock and warrants, aimed at bolstering working capital and general corporate purposes.
Capital raise
OID
BioStem Technologies has entered into a $40 million Committed Equity Facility with Roth Principal Investments, providing flexible access to capital for working capital and general corporate purposes.
Capital raise
OID
BioStem Technologies announced strong sequential revenue growth of 29% to $7.9 million for Q2 2026, raised full-year guidance, and successfully uplisted to the Nasdaq Capital Market.
Capital raise
Quarterly Earnings (10-Q)
OID
BioStem Technologies' Q3 2026 report reveals a significant revenue decrease and net loss, impacted by CMS reimbursement changes, though a recent acquisition shows promise.
Capital raise
Worse than expected
OID
BioStem Technologies' Q2 2026 Form 10-Q reveals a significant revenue decrease and increased operating costs, leading to a substantial net loss, though offset by a strategic acquisition and ongoing financing efforts.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
See all →OID
Barry Hassett, Chief Commercial Officer of Biostem Technologies, reported multiple transactions in common stock on November 1, 2026.
OID
Vurst Andrew Smith-Van, Chief Operating Officer, a Director and 10% owner of Biostem Technologies, reported multiple transactions in common stock on October 7, 2026.
OID
Jason Matuszewski, Chief Executive Officer, a Director and 10% owner of Biostem Technologies, reported multiple transactions in common stock on October 7, 2026.
OID
Vurst Andrew Smith-Van, Chief Operating Officer, a Director and 10% owner of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Jason Matuszewski, Chief Executive Officer, a Director and 10% owner of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Kenneth Howard Warrington Jr, a Director of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
New Public Companies (S-1)
OID
BioStem Technologies, Inc. has filed an S-1 registration statement for the resale of up to 2,224,270 shares of common stock by selling stockholders, amidst ongoing financial challenges and a significant revenue drop.
Capital raise
Worse than expected
OID
BioStem Technologies files for a $40 million at-the-market equity offering with Roth Principal Investments, highlighting significant dilution risks and ongoing going concern uncertainties.
Capital raise
Worse than expected
OID
BioStem Technologies files an S-1/A amendment detailing a significant revenue decrease in Q1 2026 compared to the prior year, alongside a net loss, while also outlining strategic acquisitions and future growth plans.
Worse than expected
Capital raise
OID
BioStem Technologies, Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 3,571,429 shares of common stock.
Worse than expected
Capital raise
Schedule 13G - Passive Investments
OID
Jason Matuszewski has reported beneficial ownership of 3,665,899 shares, representing 17.4% of BioStem Technologies' common stock, as of September 30, 2026.
OID
Andrew Van Vurst reports beneficial ownership of 3,854,452 shares, representing 18.4% of BioStem Technologies, Inc. common stock, primarily through vested options and direct holdings.
OID
The PNC Financial Services Group, Inc. has filed a Schedule 13G, reporting beneficial ownership of 10.40% of Biostem Technologies, Inc. common stock.